Previous Page
12-04 :: April/May 2012
nanotimes
Companies Facts
investor. Under the terms of the agreement, AMSC raised approximately $25 million in gross proceeds through the sale of convertible notes and warrants. The proceeds will be used for working capital and general corporate purposes.
A
“This financing provides an added backstop for our business as we pursue our growth and diversification strategy,” said AMSC President and Chief Executive Officer Daniel P. McGahn. “We have been meeting our business objectives and significantly reducing our cash usage. With a bolstered balance sheet, we are focusing our efforts on enabling customer success and achieving sustainable profitability.”
bution partner for Korea. Digichem, a management innovation enterprise, specializes in exporting che- mical ingredients and intermediates for markets that include paint and coatings, adhesives, automotive, electronics, pharmaceutical, printing and packaging.
A http://www.angstronmaterials.com
electronics for wireless communications from an exi- sting customer, a global mobile solutions provider.
A http://www.apitechnologies.com
PI Technologies Corp. (NASDAQ: ATNY) has received a new $1.1m order to provide critical
a
ngstron Materials Inc., has named Digichem Corporation, Anyang City, Korea, its distri-
MSC (NYSE: AMSC) has entered into a securities purchase agreement with an institutional
fiscal 2012 second quarter ended March 31, 2012. In fiscal 2012 second quarter Arrowhead acquired Alvos Therapeutics, Inc. (formerly known as Mer- cator Therapeutics, Inc.), a pioneer in targeting for tumors and tumor vasculature in humans, including a large proprietary library of human-derived targeting peptides, and received FDA clearance to initiate an Adipotide Phase I clinical trial. Moreover, the Com- pany entered into a strategic alliance and master ser- vices agreement for RNAi therapeutics with Axolabs, a German company in the field of oligonucleotide therapeutics.
A
For the quarter ended March 31, 2012, Arrowhead reported revenues of $31,250. There was no revenue in the comparable prior period. Total operating ex- penses for the quarter ended March 31, 2012 were $4.9 million, compared to $1.8 million during the quarter ended March 31, 2011.
Net loss attributable to Arrowhead for the quarter ended March 31, 2012 was $5.3 million, or $0.50 per share based on 10,663,869 weighted average shares outstanding. This compares with a net loss at- tributable to Arrowhead of $2.9 million, or $0.37 per share based on 7,891,395 weighted average shares outstanding, for the quarter ended March 31, 2011.
http://www.arrowheadresearch.com
ustriamicrosystems announced an extension of its 0.35µm High-Voltage CMOS fabrication service, offering Electrostatic Discharge (ESD) protection
rrowhead Research Corporation (NASDAQ: ARWR) announced financial results for its
15